REVIEW PAPER
Paediatric oncology and haematology in Poland: position paper
Submission date: 2018-11-08
Acceptance date: 2018-11-12
Publication date: 2019-01-07
Pediatr Pol 2018;93(6):451-461
KEYWORDS
TOPICS
ABSTRACT
Paediatric oncology is a discipline of rare diseases, defined by incidence lower than five cases per 10,000 people. Around 1160 new cases of childhood malignancies are diagnosed every year in Poland (2016–2017). The incidence rate is about 151 children per 1 million paediatric population a year. It is calculated that one out of 6600 children develops malignancy during one calendar year. Children with oncological diseases are treated in 18 centres accredited by the Polish Society of Paediatric Oncology and Haematology. Modern treatment for childhood cancer is based on multimodal therapy including multi-agent chemotherapy, radiotherapy, surgery, haematopoietic cell transplantation, and immunotherapy. All children in Poland are treated according to international therapeutic protocols in cooperation with international centres, which run as academic clinical trials. With this approach children with malignancy in Poland receive the same treatment as children in Western Europe. In this review we present current advances in diagnostics, treatment, and supportive care in paediatric oncology and haematology in Poland.
REFERENCES (60)
1.
Kowalczyk JR, Dudkiewicz E, Balwierz W, et al. Incidence of childhood cancers in Poland in 1995-1999. Med Sci Monit 2002; 8: CR587-590.
2.
Klukowska A, Urasinski T, Janik-Moszant A, et al. Prophylaxis in children with haemophilia – the Polish experience. Haemophilia 2014; 20: e108-110.
3.
Windyga J, Chojnowski K, Klukowska A, et al. Część I: Wytyczne postępowania w hemofilii A i B niepowikłanej inhibitorem czynnika VIII i IX (wydanie zaktualizowane). Acta Haematol Pol 2016; 47: 86-114.
4.
Windyga J, Chojnowski K, Klukowska A, et al. Część II: Wytyczne postępowania w hemofilii A i B powikłanej inhibitorem czynnika VIII i IX (2 wydanie). Acta Haematol Pol 2017; 47: 137-159.
5.
Janczar S, Fogtman A, Koblowska M, et al. Novel severe hemophilia A and moyamoya (SHAM) syndrome caused by Xq28 deletions encompassing F8 and BRCC3 genes. Blood 2014; 123: 4002-4004.
6.
Pastorczak A, Szczepanski T, Mlynarski W, International Berlin-Frankfurt-Munster ALLhgvwg: Clinical course and therapeutic implications for lymphoid malignancies in Nijmegen breakage syndrome. Eur J Med Genet 2016; 59: 126-132.
7.
Pastorczak A, Sedek L, Braun M, et al. Surface expression of Cytokine Receptor-Like Factor 2 increases risk of relapse in pediatric acute lymphoblastic leukemia patients harboring IKZF1 deletions. Oncotarget 2018; 9: 25971-25982.
8.
van Dongen JJ, Lhermitte L, Bottcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012; 26: 1908-1975.
9.
Kalina T, Flores-Montero J, van der Velden VH, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 2012; 26: 1986-2010.
10.
Sedek L, Bulsa J, Sonsala A, et al. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts? Cytometry B Clin Cytom 2014; 86: 329-339.
11.
Mirkowska P, Hofmann A, Sedek L, et al. Leukemia surfaceome analysis reveals new disease-associated features. Blood 2013; 121: e149-159.
12.
Lhermitte L, Mejstrikova E, van der Sluijs-Gelling AJ, et al. Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia. Leukemia 2018; 32: 874-881.
13.
Kalina T, Flores-Montero J, Lecrevisse Q, et al. Quality assessment program for EuroFlow protocols: summary results of four-year (2010-2013) quality assurance rounds. Cytometry A 2015; 87: 145-156.
14.
Theunissen P, Mejstrikova E, Sedek L, et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood 2017; 129: 347-357.
15.
Theunissen PMJ, Sedek L, De Haas V, et al. Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection. Br J Haematol 2017; 178: 257-266.
16.
Derwich K, Wachowiaki J, Kaczmarek-Kanoldi M, et al. [Treatment results in children with the standard risk acute lymphoblastic leukemia treated with high dose of methotrexate (5.0 g/m2). 11 years of the Polish Paediatric Leukemia/Lymphoma Study Group experience]. Przegl Lek 2006; 63: 7-10.
17.
Kwiecinska K, Balwierz W, Moryl-Bujakowska A, et al. [Long-term observations of children with acute lymphoblastic leukemia and high leukocytosis treated according to modified “New York” protocols (1987-2003)]. Przegl Lek 2010; 67: 350-354.
18.
Stary J, Zimmermann M, Campbell M, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol 2014; 32: 174-184.
19.
Kajdas L, Sędek Ł, Karpe J, et al. Charakterystyka kliniczna, immunofenotypowa i genetyczna ostrej białaczki limfoblastycznej u niemowląt. Post Nauk Med 2013; 24: 596-603.
20.
Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007; 370: 240-250.
21.
van der Linden MH, Valsecchi MG, De Lorenzo P, et al. Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. Blood 2009; 114: 3764-3768.
22.
Driessen EM, de Lorenzo P, Campbell M, et al. Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol. Leukemia 2016; 30: 1184-1187.
23.
Mann G, Attarbaschi A, Schrappe M, et al. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood 2010; 116: 2644-2650.
24.
Dluzniewska A, Balwierz W, Armata J, et al. Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia. Leukemia 2005; 19: 2117-2124.
25.
Balwierz W, Pawinska-Wasikowska K, Klekawka T, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in Poland. Memo 2013; 6: 54-62.
26.
Janeczko-Czarnecka M, Krawczuk-Rybak M, Karpinska-Derda I, et al. Imatinib in the treatment of chronic myeloid leukemia in children and adolescents is effective and well tolerated: Report of the Polish Paediatric Study Group for the Treatment of Leukemias and Lymphomas. Adv Clin Exp Med 2018; 27: 91-98.
27.
Wlodarski MW, Hirabayashi S, Pastor V, et al. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood 2016; 127: 1387-1397; quiz 1518.
28.
Landmann E, Burkhardt B, Zimmermann M, et al. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica 2017; 102: 2086-2096.
29.
Minard-Colin V, Brugieres L, Reiter A, et al. Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. J Clin Oncol 2015; 33: 2963-2974.
30.
Shiramizu B, Mussolin L, Woessmann W, Klapper W. Paediatric non-Hodgkin lymphoma - perspectives in translational biology. Br J Haematol 2016; 173: 617-624.
31.
Balwierz W, Armata J, Moryl-Bujakowska A, et al. Chemotherapy combined with involved-field radiotherapy for 177 children with Hodgkin’s disease treated in 1983-1987. Acta Paediatr Jpn 1991; 33: 703-708.
32.
Balwierz W, Moryl-Bujakowska A, Depowska T, et al. [Treatment regimen for children and adolescents with Hodgkin’s disease designed to decrease late complications of radiotherapy]. Med Wieku Rozwoj 2001; 5: 25-35.
33.
Balwierz W. Chłoniak Hodgkina. In: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych, Krzakowski M, Warzocha K (eds.). Via Medica 2013; 1064-1074.
34.
Trubicka J, Szperl M, Grajkowska W, et al. Identification of a novel inherited ALK variant M1199L in the WNT type of medulloblastoma. Folia Neuropathol 2016; 54: 23-30.
35.
Lastowska M, Trubicka J, Niemira M, et al. ALK Expression Is a Novel Marker for the WNT-activated Type of Pediatric Medulloblastoma and an Indicator of Good Prognosis for Patients. Am J Surg Pathol 2017; 41: 781-787.
36.
Lastowska M, Trubicka J, Niemira M, et al. Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis. J Neurooncol 2018; 138: 231-240.
37.
Balwierz W, Wieczorek A, Klekawka T, et al. [Treatment results of children with neuroblastoma: report of Polish Pediatric Solid Tumor Group]. Przegl Lek 2010; 67: 387-392.
38.
Balwierz W. Różne aspekty związane z diagnostyką i leczeniem nerwiaka zarodkowego współczulnego. Onkologia po Dyplomie 2015: 2-6.
39.
Balwierz W, Szurgot M. Nerwiak zarodkowy współczulny. In: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych, Krzakowski M, Warzocha K (eds.). Via Medica 2013; 1082-1098.
40.
Pietras W. Advances and changes in the treatment of children with nephroblastoma. Adv Clin Exp Med 2012; 21: 809-820.
41.
Stegmaier S, Leuschner I, Poremba C, et al. The prognostic impact of SYT-SSX fusion type and histological grade in pediatric patients with synovial sarcoma treated according to the CWS (Cooperative Weichteilsarkom Studie) trials. Pediatr Blood Cancer 2017; 64: 89-95.
42.
Ciesla M, Marona P, Kozakowska M, et al. Heme Oxygenase-1 Controls an HDAC4-miR-206 Pathway of Oxidative Stress in Rhabdomyosarcoma. Cancer Res 2016; 76: 5707-5718.
43.
Sparber-Sauer M, Seitz G, von Kalle T, et al. Alveolar soft-part sarcoma: Primary metastatic disease and metastatic relapse occurring during long-term follow-up: Treatment results of four Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry. Pediatr Blood Cancer 2018; 65: e27405.
44.
Raciborska A, Bilska K, Drabko K, et al. Validation of a multi-modal treatment protocol for Ewing sarcoma – a report from the polish pediatric oncology group. Pediatr Blood Cancer 2014; 61: 2170-2174.
45.
Bus MP, Szafranski A, Sellevold S, et al. LUMiC((R)) Endoprosthetic Reconstruction After Periacetabular Tumor Resection: Short-term Results. Clin Orthop Relat Res 2017; 475: 686-695.
46.
Raciborska A, Bilska K. Sorafenib in patients with progressed and refractory bone tumors. Med Oncol 2018; 35: 126.
47.
Frazier AL, Hale JP, Rodriguez-Galindo C, et al. Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States. J Clin Oncol 2015; 33: 195-201.
48.
Shaikh F, Murray MJ, Amatruda JF, et al. Paediatric extracranial germ-cell tumours. Lancet Oncol 2016; 17: e149-e162.
49.
Olson TA, Murray MJ, Rodriguez-Galindo C, et al. Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. J Clin Oncol 2015; 33: 3018-3028.
50.
Dembowska-Bagińska B, Rutynowska-Pronicka O, Kołodziejczyk-Gietka A, et al. Intra-arterial chemotherapy (IAC) for patients with retinoblastoma (RB) treated in one center. Pediatr Blood Cancer 2017: 64 (Supl 3): S273.
51.
Bien E, Godzinski J, Dall’igna P, et al. Pancreatoblastoma: a report from the European cooperative study group for paediatric rare tumours (EXPeRT). Eur J Cancer 2011; 47: 2347-2352.
52.
Bisogno G, Ferrari A, Bien E, et al. Rare cancers in children – The EXPeRT Initiative: a report from the European Cooperative Study Group on Pediatric Rare Tumors. Klin Padiatr 2012; 224: 416-420.
53.
Ferrari A, Schneider DT, Bisogno G, Board EX. The founding of the European Cooperative Study Group on Pediatric Rare Tumors – EXPeRT. Expert Rev Anticancer Ther 2013; 13: 1-3.
54.
Wachowiak J, Chybicka A, Kowalczyk JR, et al. Development and current use of in hematopoietic stem cell transplantation in children and adolescents in Poland: Report of the Polish pediatric study group for hematopoietic stem cell transplantation of the Polish society for pediatric oncology and hematology. Transfus Apher Sci 2018; 57: 316-322.
55.
Styczynski J, Czyzewski K, Wysocki M, et al. Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional anticancer therapy: a multicentre nationwide study. Clin Microbiol Infect 2016; 22: 179e171-179e110.
56.
Zajac-Spychala O, Wachowiak J, Szmydki-Baran A, et al. Infectious complications in children treated for hodgkin and non-hodgkin lymphomas in polish pediatric leukemia/lymphoma study group: incidence, epidemiology and etiology. Leuk Lymphoma 2018: 1-9.
57.
Kowalczyk JR, Samardakiewicz M, Pritchard-Jones K, et al. European Survey on Standards of Care in paediatric oncology centres. Eur J Cancer 2016; 61: 11-19.
58.
Muczyń A, Sterczyński R, Samardakiewicz M, et al. PedsQL™ Cancer Module as a method to assess the quality of life of children with malignancies of the hematopoietic system: linguistic validation and a pilot studies. Psychoonkologia 2015; 19: 138-145.
59.
Grudzińska M, Samardakiewicz M. PAT2.0 as a method identifying the psychosocial needs of families of children with cancer in Polish conditions. Psychoonkologia 2012; 16: 55-58.
60.
Krawczuk-Rybak M, Panasiuk A, Stachowicz-Stencel T, et al. Health status of Polish children and adolescents after cancer treatment. Eur J Pediatr 2018; 177: 437-447.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
